ECSP18046355A - Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson - Google Patents
Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinsonInfo
- Publication number
- ECSP18046355A ECSP18046355A ECIEPI201846355A ECPI201846355A ECSP18046355A EC SP18046355 A ECSP18046355 A EC SP18046355A EC IEPI201846355 A ECIEPI201846355 A EC IEPI201846355A EC PI201846355 A ECPI201846355 A EC PI201846355A EC SP18046355 A ECSP18046355 A EC SP18046355A
- Authority
- EC
- Ecuador
- Prior art keywords
- diagnosis
- disease
- prognosis
- parkinson
- alzheimer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Abstract
La presente invención es la proteína de lactoferrina, o un ácido nucleico que la codifique, para uso en el diagnóstico o pronóstico de la enfermedad de Alzheimer (EA). La invención es un método de diagnóstico o pronóstico de EA en un paciente, que comprende evaluar el nivel de lactoferrina en la saliva o en una muestra de saliva de dicho sujeto y determinar si dicho nivel es superior o inferior a un valor de 7,43 µg/ml, donde un valor inferior a 7,43 µg/ml es indicativo de EA o del pronóstico de EA. Otro aspecto es la proteína de lactoferrina, o un ácido nucleico que la codifique, para uso en el diagnóstico de la enfermedad de Parkinson (EP) en una muestra de saliva de un sujeto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15195662.0A EP3171174B1 (en) | 2015-11-20 | 2015-11-20 | Lactoferrin for use in the diagnosis or prognosis of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP18046355A true ECSP18046355A (es) | 2018-09-30 |
Family
ID=54697475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201846355A ECSP18046355A (es) | 2015-11-20 | 2018-06-19 | Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11422137B2 (es) |
| EP (2) | EP3171174B1 (es) |
| JP (1) | JP6991970B2 (es) |
| KR (1) | KR102579727B1 (es) |
| CN (1) | CN108431608B (es) |
| AU (1) | AU2016354981B2 (es) |
| BR (1) | BR112018010266A2 (es) |
| CA (1) | CA3005784C (es) |
| CL (1) | CL2018001343A1 (es) |
| CO (1) | CO2018006298A2 (es) |
| CY (1) | CY1119797T1 (es) |
| DK (1) | DK3171174T3 (es) |
| EC (1) | ECSP18046355A (es) |
| ES (1) | ES2657414T3 (es) |
| HR (1) | HRP20180115T1 (es) |
| HU (1) | HUE037916T2 (es) |
| LT (1) | LT3171174T (es) |
| MD (1) | MD3171174T2 (es) |
| ME (1) | ME02993B (es) |
| MX (1) | MX2018006189A (es) |
| NO (1) | NO3171174T3 (es) |
| PL (2) | PL3171174T3 (es) |
| PT (1) | PT3171174T (es) |
| RS (1) | RS56832B1 (es) |
| RU (1) | RU2745602C2 (es) |
| SI (1) | SI3171174T1 (es) |
| WO (1) | WO2017085214A1 (es) |
| ZA (1) | ZA201804079B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201818373A2 (tr) | 2018-12-03 | 2020-06-22 | T C Erciyes Ueniversitesi | Bağirsak mi̇krobi̇yomundan alzhei̇mer hastaliğinin teşhi̇si̇ i̇çi̇n mi̇ni̇mal bi̇yobeli̇rteçler ve i̇lgi̇li̇ yeni̇ nesi̇l di̇zi̇leme ki̇ti̇ |
| CN112142850A (zh) * | 2019-06-27 | 2020-12-29 | 深圳市卫光生物制品股份有限公司 | 人神经生长因子-乳铁蛋白重组蛋白及用途 |
| CN111415745A (zh) * | 2020-04-03 | 2020-07-14 | 河北医科大学 | 一种雄激素提示老年男性阿尔茨海默病风险的计算方法 |
| CN113049696B (zh) * | 2021-03-04 | 2022-03-18 | 首都医科大学宣武医院 | 一种诊断受试者是否患阿尔茨海默病的代谢产物及其用途 |
| CN113967250A (zh) * | 2021-09-26 | 2022-01-25 | 四川大学 | 乳铁蛋白在预防治疗阿尔兹海默症中的应用 |
| CN114242175A (zh) * | 2021-12-22 | 2022-03-25 | 香港中文大学深圳研究院 | 一种评估脑白质高信号体积的方法及系统 |
| CN115737787B (zh) * | 2022-12-15 | 2024-04-19 | 四川大学 | 乳铁蛋白联合胆碱在制备预防和/或治疗阿尔兹海默症的药物中的用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94183A (en) * | 1989-05-05 | 2003-09-17 | Baylor College Medicine | cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE |
| US7192724B2 (en) * | 2000-11-14 | 2007-03-20 | Techlab, Inc. | Method for differentiating irritable bowel syndrome from inflammatory bowel disease (IBD) and for monitoring persons with IBD using total endogenous lactoferrin as a marker |
| US20030096736A1 (en) | 2001-05-09 | 2003-05-22 | Kruzel Marian L. | Lactoferrin for age related disorders in humans |
| CA2502976C (en) * | 2002-10-25 | 2012-05-22 | Techlab, Inc. | Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel |
| WO2009074331A2 (en) | 2007-12-11 | 2009-06-18 | Julius-Maximilians-Universität Würzburg | Early and differential diagnosis test for alzheimer's disease |
| EP2389289A4 (en) * | 2009-01-23 | 2012-11-07 | Univ Drexel | APPARATUS AND METHODS FOR DETECTING INFLAMMATION USING QUANTUM POINTS |
| EP2251032A1 (en) | 2009-05-12 | 2010-11-17 | Nestec S.A. | Lactoferrin and brain health and protection in adults |
| CA2765099A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Phosphorylated tau peptide for use in the treatment of tauopathy |
| US20110236917A1 (en) | 2009-11-17 | 2011-09-29 | Power3 Medical Products, Inc. | Diagnosis of Alzheimer's Disease |
| RU2563987C2 (ru) * | 2010-10-20 | 2015-09-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Биомаркер для болезни альцгеймера или умеренного когнитивного расстройства |
| EP2734543B1 (en) * | 2011-07-24 | 2018-10-03 | Carmel-Haifa University Economic Corp. | Lactoferrin fragments and use thereof |
| CA2877975C (en) | 2012-04-13 | 2021-09-21 | Oasis Diagnostics Corporation | Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases |
| CN103575903B (zh) * | 2012-08-07 | 2016-01-20 | 中国检验检疫科学研究院 | 一种人乳铁蛋白夹心elisa检测试剂盒及其应用 |
-
2015
- 2015-11-20 HU HUE15195662A patent/HUE037916T2/hu unknown
- 2015-11-20 SI SI201530160T patent/SI3171174T1/en unknown
- 2015-11-20 ME MEP-2018-12A patent/ME02993B/me unknown
- 2015-11-20 PT PT151956620T patent/PT3171174T/pt unknown
- 2015-11-20 NO NO15195662A patent/NO3171174T3/no unknown
- 2015-11-20 LT LTEP15195662.0T patent/LT3171174T/lt unknown
- 2015-11-20 MD MDE20170031T patent/MD3171174T2/ro unknown
- 2015-11-20 EP EP15195662.0A patent/EP3171174B1/en active Active
- 2015-11-20 RS RS20180039A patent/RS56832B1/sr unknown
- 2015-11-20 DK DK15195662.0T patent/DK3171174T3/en active
- 2015-11-20 ES ES15195662.0T patent/ES2657414T3/es active Active
- 2015-11-20 PL PL15195662T patent/PL3171174T3/pl unknown
-
2016
- 2016-11-17 AU AU2016354981A patent/AU2016354981B2/en active Active
- 2016-11-17 RU RU2018122111A patent/RU2745602C2/ru not_active Application Discontinuation
- 2016-11-17 CO CONC2018/0006298A patent/CO2018006298A2/es unknown
- 2016-11-17 CA CA3005784A patent/CA3005784C/en active Active
- 2016-11-17 US US15/776,462 patent/US11422137B2/en active Active
- 2016-11-17 MX MX2018006189A patent/MX2018006189A/es unknown
- 2016-11-17 BR BR112018010266A patent/BR112018010266A2/pt unknown
- 2016-11-17 EP EP16809652.7A patent/EP3377909B1/en active Active
- 2016-11-17 WO PCT/EP2016/078060 patent/WO2017085214A1/en active Application Filing
- 2016-11-17 JP JP2018526624A patent/JP6991970B2/ja active Active
- 2016-11-17 KR KR1020187017108A patent/KR102579727B1/ko active IP Right Grant
- 2016-11-17 PL PL16809652T patent/PL3377909T3/pl unknown
- 2016-11-17 CN CN201680076298.1A patent/CN108431608B/zh active Active
-
2018
- 2018-01-22 HR HRP20180115TT patent/HRP20180115T1/hr unknown
- 2018-01-23 CY CY20181100083T patent/CY1119797T1/el unknown
- 2018-05-18 CL CL2018001343A patent/CL2018001343A1/es unknown
- 2018-06-18 ZA ZA2018/04079A patent/ZA201804079B/en unknown
- 2018-06-19 EC ECIEPI201846355A patent/ECSP18046355A/es unknown
-
2022
- 2022-07-29 US US17/876,923 patent/US20230081393A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18046355A (es) | Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson | |
| CY1123746T1 (el) | Ανθρωποποιημενα tau αντισωματα σε νοσο του alzheimer | |
| CY1119766T1 (el) | Νεοι ρυθμιστες κινασης βενζοπυρανιου | |
| EA201792501A1 (ru) | Вакцины для лечения и профилактики рака | |
| MX2017006785A (es) | Metodos y composiciones para radioetiquetado con 18f de productos biologicos. | |
| CO2017009150A2 (es) | Composiciones para el cuidado oral que comprenden arginina o lisina, óxido de zinc, una fuente de fluoruro y un abrasivo de sílice | |
| EP3626832A3 (en) | Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease | |
| CY1124143T1 (el) | Οστικες μορφογενετικες πρωτεϊνες | |
| MX2018014028A (es) | Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet). | |
| MX2022002056A (es) | Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina. | |
| MX2017009038A (es) | Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes. | |
| MX2018001697A (es) | Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores. | |
| PH12019550236A1 (en) | Detection of misfolded tau protein | |
| MX2022010954A (es) | Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo. | |
| WO2015168602A3 (en) | Methods and compositions for the diagnosis and treatment of kawasaki disease | |
| BR112019000946A2 (pt) | compostos para imagiologia dos agregados da proteína tau | |
| FR3003173B1 (fr) | Substituts osseux greffes par des peptides mimetiques de la proteine humaine bmp-2. | |
| WO2017053792A8 (en) | Method for determining the in vivo comparability of biologic drug and a reference drug | |
| WO2014053110A3 (de) | Peptide zur behandlung und frühdiagnose von morbus alzheimer und anderer tauopathien | |
| WO2018026969A3 (en) | Plazomicin antibodies and methods of use | |
| EP3642366C0 (en) | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR DIAGNOSING ALZHEIMER’S DISEASE | |
| MX2016014779A (es) | Prueba de diagnostico y tratamiento/prevencion de la enfermedad de alzheimer. | |
| ITMI20120865A1 (it) | Biomarcatori per patologie del sistema nervoso centrale | |
| WO2017053718A3 (en) | Biomarkers for the early detection of parkinson's disease | |
| MA40065A (fr) | N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson |